comparison of glp-1 agonists GLP-1-based therapies: current knowledge differences between native Mapping the effectiveness and risks

Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists

Monjouro/Zepbound is a GIP (glucose-dependent insulinotropic polypeptide) and GLP - 1 receptor agonist

Bit of Background These new classes of antiobesity medications (ie, the GLP-1 agonists and dual agonists), referred to in this article as weight management medications, arent really new.1-4 The basic science and pharmaceutical research and development to bring these to market began more than two decades ago when two scientists, Matthias Tschop, MD, and Richard DiMarchi, PhD, hypothesized that the actions of various gut hormones may offer safe and unprecedented weight loss

This means survodutide may provide additional benefits for fat loss specifically, particularly visceral and liver fat, beyond what GIP/GLP-1 dual agonism achieves

11 While a number of different non-medication options exist for treatment of OSA, including lifestyle modifications, breathing devices, oral appliances, and surgical procedures, tirzepatide was approved by the FDA for moderate to severe obstructive sleep apnea in late 2024

A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus